Document is current
Any future updates will be listed below
-
Authors
Zhao, Xin
Zhang, Xinyu https://orcid.org/0009-0005-3138-681X
Yuan, Shiying https://orcid.org/0000-0002-6415-1604
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
Zhang, Jiancheng https://orcid.org/0000-0002-2820-0851
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82272231)
National Natural Science Foundation of China (82472223)
- License Information
-
More Information
Article History
Received: 19 August 2025
Revised: 3 March 2026
Accepted: 23 March 2026
First Online: 13 April 2026
Competing interests
: Dr. Hashimoto is one of the editorial board members of this journal. Dr. Hashimoto is the inventor of filed patent applications on “The use of (R)-ketamine in the treatment of psychiatric diseases”, “(S)-norketamine and salt thereof as pharmaceutical”, “(R)-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “(R)-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto also declares that he has received research support from Otsuka (Japan). Other authors declare no conflict of interest.
